Kristoffer Staal Rohrberg

Kristoffer Staal Rohrberg serves as a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences, based at Copenhagen University Hospital, Rigshospitalet (Blegdamsvej 3, 2200 Copenhagen N). His primary clinical and research activities center on the hospital's Phase 1 Unit, where he conducts early-phase oncology trials and cancer genomics research.

His research spans translational oncology with emphases on solid tumor immunology, genetic heterogeneity, and biomarker-driven therapies. Key focus areas include HRD status dynamics, Treg-targeting immunotherapies, bispecific antibody mechanisms, and molecular characterization of uveal melanoma and urothelial cancers. His work integrates genomic analysis with clinical trial design to address treatment resistance mechanisms in head and neck, urothelial, and rare cancers.

Analysis of his 2023-2025 publications reveals a dominant trend in multi-institutional Phase 1 trials testing novel immunotherapies (RG6292, cibisatamab) combined with checkpoint inhibitors. His research consistently addresses tumor evolution through longitudinal genomic studies, with significant contributions to understanding intratumor heterogeneity across cancer types. Collaborative networks span European and North American institutions, reflecting the global nature of his clinical trial work.

Dr. Rohrberg actively contributes to Rigshospitalet's Phase 1 Unit, leading genomic analyses for early-stage therapeutic trials. His research teams integrate molecular diagnostics with clinical oncology, utilizing multi-omics approaches to identify predictive biomarkers. Current projects focus on Treg modulation strategies and pan-cancer HRD assessment, with strong translational links to therapeutic decision-making in refractory solid tumors.